GS-09-Ramucirumab for patients with advanced hepatocellular carcinoma and elevated alpha-fetoprotein following sorafenib: Outcomes by liver disease aetiology from two randomised, placebo-controlled phase 3 studies (REACH-2 and REACH)
Journal of Hepatology（2019）
Key words
advanced hepatocellular carcinoma,hepatocellular carcinoma,sorafenib,liver disease aetiology,alpha-fetoprotein,placebo-controlled
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined